Nevertheless, the contribution of BCL-2 to MCL-1 inhibition is minor compared to the one observed with BCL-xL, indicating that the anti-apoptotic MCL-1/BCL-xL axis is the predominant one in breast cancer, as previously reported [55]. Here, BCL2L1 is linked to breast carcinoma.